Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open Label, Multicenter, Phase I/II Study of Belantamab Mafodotin in Combination With Kd for the Treatment of Relapsed Myeloma Patients, Refractory to Lenalidomide.

NCT05060627 is registered in ClinicalTrials.gov with PETHEMA Foundation as lead sponsor.

NCT NCT05060627
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05060627 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open Label, Multicenter, Phase I/II Study of Belantamab Mafodotin in Combination With Kd for the Treatment of Relapsed Myeloma Patients, Refractory to Lenalidomide.
Lead sponsor
PETHEMA Foundation
Phase
Phase 1/2
Overall status
Active, not recruiting
Start date
December 20, 2021
Completion date
May 30, 2028
Enrollment
60 (estimated)
Sites
15

Conditions

As the registry lists them; a condition with its own page is linked.

relapsed multiple myeloma